Norwegian general population normative data for the EORTC questionnaires; the core QLQ-C30, the sexual health questionnaire QLQ-SHQ22, and sexual domains of the QLQ-BR23/BR45.

Åsberg, R.E¹, Nilsen, M², Hjermstad, M.J⁵, Reinertsen, K.V⁶, Karlsen, J^{8,9}, Giskeødegård, G.F^{3,4}, Reidunsdatter, $R.J.^1$

Abstract

Objective: The aim of this study was to provide gender-, age-, and morbidity-specific Norwegian general population normative values for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires QLQ-C30, the sexual health questionnaire QLQ-SHQ22, and the sexual domains of the breast modules QLQ-BR23 and QLQ-BR45.

Methods: A random nation-wide sample stratified by gender and age groups (18–29, 30-39, 40–49, 50–59, 60–69 and ≥70 years) was drawn from the Norwegian National Population Register. Participants were notified through National online health services (HelseNorge) and by postal mail. The survey included sociodemographic background information, HRQoL assessed by the EORTC questionnaires, and morbidity by The Self-Administered Comorbidity Questionnaire. Multivariable linear regression was carried out to estimate the associations of age, sex, and morbidity with the EORTC scale and item scores.

Results: Of the 15,627 eligible individuals, 5.135 (33%) responded. Women and persons with morbidities reported lower functioning and higher symptom burden than men and persons without morbidities, respectively, on nearly all EORTC scales. Sex differences were most prominent for Emotional Functioning, Pain, Fatigue, and Insomnia (QLQ-C30), Body Image, Sexual Functioning (QLQ-BR23/45), Importance of Sexual Activity, Libido, and Fatigue (QLQ-SHQ22). The score differences between persons with and without morbidity were highly significant and largest among the youngest and middle-aged groups.

Conclusion: The present study is the first to provide normative values for the EORTC sexual health questionnaire OLO-SHO22 and the sexual subscales of the OLO-BR23 and OLO-BRIEST his predring reparts new research that has not been sextified by near triviting and should not be used to guide clinical practice.

¹ Department of Circulation and Medical Imaging, Faculty of Medicine, and Health Sciences, NTNU

² Department of Social Work, Faculty of Social and Educational Sciences, NTNU

³ K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU

⁴ Department of Surgery, St. Olavs University Hospital

⁵ Regional Advisory Unit for Palliative Care, Dept. of Oncology, Oslo University Hospital / European Palliative Care Research Centre (PRC) and Institute of Clinical Medicine, University of Oslo, Oslo

⁶ Department of Oncology, Oslo University Hospital

⁷ National Advisory Unit for Late effects After Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo

⁸ Department of Oncology, St.Olav's Hospital, Trondheim University Hospital, Trondheim, Norway

⁹ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway

Keywords: Health-Related Quality of Life, HRQOL, normative values, Norwegian general population, patient-reported outcomes, PROMs, EORTC QLQ-C30, QLQ-BR23, QLQ-BR45, QLQ-SH22, co-morbidity, sexual scales, cancer.

Introduction

Patient-reported outcome measures (PROMs) reflect the patients' own perceptions of healthrelated quality of life (HRQoL) [1, 2]. The purpose of PROMs in oncology is to provide valuable information on how cancer and treatment affect short- and long-term HRQoL and thereby guide clinicians in patient-centered care [3-5]. PROMs are recognized as independent endpoints in clinical studies and health care research worldwide [6].

One of the most frequently used PROMs in oncology is the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [5, 7]. This cancer specific core questionnaire is often supplemented by modules for specific diagnoses or conditions, e.g. the breast cancer modules QLQ-BR23 / QLQ-BR45 [8, 91.

Even though these questionnaires are validated and frequently used, meaningful and consistent interpretations of scores remain challenging in both research and clinical practice [10-12]. One approach is to compare changes in PROMs at the group or patient level using clinically significant differences [13]. For interpretation of EORTC scores obtained at certain time points, thresholds for high symptom scores or low functional scores have been utilized [14, 15], and for the core EORTC QLQ-C30, thresholds clinical importance of domains have recently been developed [16]. General population data provide estimates of HRQOL scores of the same age and sex as the patients, and thereby supporting the interpretation of PROMs in clinical practice and cancer studies [17-20].

Sexual health is an important aspect of HRQoL [21, 22], and sexual problems have a high prevalence of in cancer survivors [23]. Despite this fact, the only normative EORTC data on sexual health are from a Dutch normative study incorporating five sexual single items from the EORTC's item bank [24]. So far sexual concerns have been covered by a few items in some the EORTC modules, e.g., the two breast cancer modules QLQ-BR23 and QLQ-BR45 [8, 9] Thus, EORTC has recently developed a standalone Sexual Health Questionnaire (OLO-SHQ22) for a more comprehensive assessment of sexual health [25]. To date, no normative data on sexual health have been published from Scandinavia.

Perceived HRQoL varies by age and sex and during the life course [17, 20, 26-29], and further, poor health condition has a great negative impact on HRQOL [5, 19, 27, 30]. Hence, a valid assessment of morbidity should be included in the collection of normative data, and comorbidity should be accounted for in comparisons with cancer populations. As such, normative data may provide information about health issues that are probably due to the cancer or treatment or simply an effect of normal ageing, morbidities or sex differences [5, 19, 27, 31] Country-specific normative values have been conducted for European countries, included Norway in 1998 and 2007 [30, 32], showing national differences [5, 18-20, 24, 27-

29, 31, 33-38]. Updated data are essential to display the current HRQoL in the Norwegian general population.

The primary aim of this study was to provide sex and age specific normative values from the Norwegian general population for HRQoL, including sexual health addressed by the EORTC questionnaires QLQ-C30, QLQ-SHQ22, and the sexual domains of QLQ-BR23 and QLQ-BR45.

Methods

Study procedure and participants

The study was designed as a nationwide electronic and postal cross-sectional survey. The web solution eFORSK (https://www.klinforsk.no/info/Informasjon), developed by the Central Norway Regional Health Authority IT department (HEMIT) and run by the Norwegian Health Network (NHN), was utilized for data collection. A pilot study including 15 participants was performed to test the comprehensibility of the survey and the usability of the digital platform (eFORSK) for data collection, and adaptations were carried out accordingly.

The Norwegian Tax Administration gave permission to draw a randomly selected sample (N=15.627) from the Norwegian National Population Register stratified by gender and age. This sample size was estimated to ensure sufficient sample sizes for age subgroups (18-29, 30–39, 40–49, 50–59, 60–69 and \geq 70 years). The data extraction was executed by the national IT-company Evry (Evry.com). To increase the response rate, the randomly selected participants received a digital postcard informing them about the upcoming study a week ahead of the survey release. The study was promoted to the general audience in social media, national and local newspapers, blogs, podcasts, external channels at Norwegian University of Science and Technology (NTNU), and in national radio news.

The survey was released from eFORSK in the period August to November 2021. Participants were consecutively notified and informed through the National online health services "Helsenorge", the digital mailbox "Digipost", e-mail or SMS. Digitally unreachable individuals (n=42) received the survey by postal mail. One reminder was sent after two weeks to the digital responders.

Measures

Age, gender, and habitation were automatically collected from the National Population Register through eFORSK. Sociodemographic information regarding marital status, living situation, education, profession, employment status and income were included as selfreported background information in the survey.

HRQoL was assessed by the EORTC QLQ-C30 questionnaire [7] consisting of one global health/quality of life scale, five functional scales (physical-, role-, cognitive-, emotional- and social functioning), 3 symptom scales (fatigue, nausea, pain) and 6 single items [39].

perpetuity.

It is made available under a CC-BY 4.0 International license .

Sexual health was assessed by the EORTC sexual health questionnaire QLQ-SHQ22 [40]. It consists of eight functional scales measuring *sexual satisfaction* (among the sexually active), *importance of sexual activity* (with or without partner), *libido, impact of treatment, communication with professionals about sexual problems, insecurity with partner* (among those with partner), *femininity* (women only), *masculinity and confidence with erection* (men only), and four symptom scales assessing the impact of *sexual pain, worry about incontinence, fatigue, and vaginal dryness* (women only). The instrument has proven psychometric properties and is found applicable in research and clinical practice for assessing sexual health in both survivors and patients, across diagnosis and stages of disease, [25].

Sexual health items from the breast cancer modules QLQ-BR23 and QLQ-BR45 (not covered by the SHQ22) were added to the survey [8, 9]. These include all items in the functional scales *body image, sexual functioning, and sexual enjoyment* (in BR23/45) in addition to symptom items in the BR45-scales: *Endocrine Therapy Symptoms* and *Endocrine Sexual Symptoms* about pain or stiffness in joints or bones, pain in muscles, weight gain, mood alteration and menopausal status. As the QLQ-BR45 is not yet in Norwegian, the used items were translated by the research team according to EORTC translation manual.

Response options for all the items are *Not at all* (1) to *Very much* (4), except for the two global health / QoL items ranging from *Very poor* (1) to *Excellent* (7). To strengthen the face validity and content validity in a general population, the three items asking whether disease or treatment has impact various life conditions were given an extra response option "Not relevant". The recall period was one week for the general health items and four weeks for the sexual items in BR23/45 and SHQ22. Scales were transformed into 0-100 scale following the EORTC scoring manual. Higher scores indicate better functioning/quality of life and higher symptom burden [41].

Morbidity was assessed by *The Self-Administered Comorbidity Questionnaire (SCQ)* [39]. The SCQ addresses the presence of up to 15 health conditions, whether the person receives treatment, and whether the condition limits any activities. In our study, morbidity was defined as having one or more morbidities that limited activities.

Statistical analyses

Normative values are presented in six age groups (18-29, 30-39, 40-49, 50-59, 60-69 and ≥ 70 years) by means and SD, by gender and morbidity. Mean scores by gender and morbidity for all functional scales and for the most prominent symptoms were illustrated by graphs (mean, 95% CI). Group differences were tested by student t-tests. Floor and ceiling effects were calculated for the scales in QLQ-C30 and QLQ-SHQ22.

Multivariable linear regression was carried out to estimate the associations of each EORTC QLQ-C30 scale with age and gender, gender-age interaction and morbidity (0=none, 1= one or more conditions limiting activities). To predict scores for the EORTC QLQ-C30 scales for individuals or groups at a certain age and morbidity, we developed a regression model following procedures of previous publications [5, 42] (Supplementary Table II).

Ethics

The study was approved by the Regional Committee for Medical Research Ethics (REK 2020/58888). Study information was enclosed to the survey with completion regarded as informed consent.

Results

Participants

A total of 5,135 individuals responded, giving an overall response rate of 33% with almost equal gender proportion (Table I). The vast majority (99%) responded digitally (Supplementary Table I), and participant characteristics are shown in Table II.

Normative data for EORTC QLQ-C30

Normative scores for the EORTC QLQ-C30 scales are presented in *Table III*. The most prominent symptoms were fatigue, insomnia, and pain. Floor and ceiling effects are displayed in Supplementary Table II. The regression model for predicting individual EORTC QLQ-C30 normative scores for age-, sex- and morbidity is provided in *Table IV*.

Women reported generally lower functioning and higher symptom scores than men. Gender differences were most pronounced for emotional functioning, pain, fatigue, and insomnia. The youngest women (18-29 years) reported poorer emotional function (9.4 points) and more fatigue (11.4 point), and the older women (59-79 years) reported more pain (8.2 points) and sleep problems (9.5 point) compared to men in the corresponding age groups (Figure I, Table III).

Respondents with morbidities scored significantly lower on global QOL and functional scales and higher on symptom scales than persons without morbidities across all age-groups, Figure II. The largest differences were observed among the youngest (18-29 years) on emotional and cognitive functioning (32 and 28 points). Physical functioning was most divergent in the middle aged (15 points) and oldest age group (19 points).

Among symptoms, *Insomnia and Fatigue* displayed the largest differences between persons with and without morbidities among the youngest (25 and 31 points) and middle-aged groups (26 points on both symptoms), whereas pain differences were largest in the middle-aged group (28 points). All group differences were highly significant (p<0.001).

Normative data for EORTC QLQ-SHQ22 and the sexual scales in EORTC QLQ-BR23 and QLQ-BR45

Normative scores for the EORTC QLQ-SHQ22 and sexual scale scores from the EORTC QLQ-BR23/BR45 are presented in *Table V*. Floor and ceiling effects are displayed in Supplementary Table III. Among symptoms Fatigue influenced sexual life most (Figure III, Table V).

Women reported generally lower functioning and higher symptom scores than men (Figure IV). Gender differences in the functional scales were most pronounced for Importance of Sexual Activity (22 points), Libido (20 points), Body Image particularly among the youngest (20 points, 18-29 years), and Sexual Functioning which differed by 10-13 points between genders from the age of 30-69 years.

The influence of Fatigue on sexual life was most gender divergent among the youngest (18-39 years) and middle-aged groups (40-59 years) with a gap between 14 and 17 points (Figure III and Table V).

Respondents with morbidities scored in general lower on functioning and higher on symptoms than persons without morbidities, as illustrated in Figure IV. The largest mean difference was observed in men with and without comorbidities on masculinity aged 40-49 years with a gap of 30 points. In both genders Sexual Satisfaction, Libido, Security with partner, Body Image and Sexual Enjoyment were significantly lower in persons with morbidities with most pronounced differences among the youngest and middle-aged. Treatment had significantly more impact on sexual life in persons with morbidities, and the youngest men (18-39 years) with morbidities had significantly less Confident in erection.

The influence of *Fatigue* on sexual life displayed the largest differences among the youngest and the middle-aged group (26 points, 18-49 years) between persons with and without morbidities (Figure IV). Among women, Endocrine Therapy Symptoms (which reflected mood swings, pain or stiffness joints, bones and muscles and weight gain) was most divergent in the middle-aged group (19 points) and Femininity in the age group 60-60 years (21 points). Group differences were all highly significant (p<0.001).

Discussion

The present study provides new Norwegian general population normative values on the EORTC QLQ-C30 and is the first study to present normative values on the EORTC sexual health questionnaire QLQ-SHQ22, and the sexual scales in QLQ-BR23 and QLQ-BR45.

Global health/QoL, emotional and cognitive functioning increased by age in the Norwegian population, in line with recent studies in Italy [5] and Australia [43], but in contrast to previous normative studies in Europe [32, 34, 36, 44]. This pattern could be due to an improved health care system and a healthier lifestyle among present elderly citizens.

The most prominent symptoms were fatigue, insomnia, and pain, similar to the Italian [5], Swedish [28], Danish [19], and the previous Norwegian normative population samples [30, 32]. However, compared to prior EORTC studies, a new symptom distribution across agegroups was observed where fatigue and insomnia were more severe among the youngest age groups, and particularly among women. Increased fatigue among the youngest was also found in recent Norwegian normative studies of generic HRQoL questionnaires [45, 46], and similar trends of higher symptom burden among the youngest has been found in the latest European normative studies [5, 20, 27]. This pattern may be explained by high influence of

social media, high demands and often many options to navigate between among youths of today.

Norwegian women reported more symptoms and lower functioning than men, in line with previous studies [5, 17, 19, 20, 27-29]. Gender differences were more prominent in the Norwegian population than in the German [47] and Danish populations[19], but in line with findings in recent Italian study [5]. However, the distinction in score patterns between groups defined by having morbidity or not, were far more pronounced than sex differences, and congruent to other norm studies with valid detection of morbidities [5, 19, 20, 27, 48].

Normative scores for sexual health are the first of its kind; for EORTC QLQ-SHQ22 worldwide and for BR-23/45 in Scandinavia, though such knowledge is highly required both in research and clinical use [24]. Gender differences were even more pronounced in the sexual dimensions of HROOL, particularly among the youngest age groups where females scored lower. The most striking result was the huge gender gap in the functional scales *Body* Image, Libido, Sexual Functioning, and Importance of Sexual Activity. Among the symptom scales, the impact of *Fatigue* on sex life was most prominent in the age groups from 30-59 and may explain some of the low sexual functioning scores in these age groups. Morbidities had a generally negative impact on all sexual domains, except for the importance of sexual activity. The Norwegian general population report nearly no communication with healthcare professionals about sexual topics, in line with frequently described barriers in the patientclinician interaction around sexual health [49, 50].

Limitations of the present study could be the response rate of 35%, which might threaten the generalizability to the general population. However, adding questions about sensitive topics implies an increased risk of lower response rate [24]. We tried to counteract this through several efforts in the data collection process. The response rate, 35% for women and 31% for men, was evidently lower than in panel data studies [20, 24, 31], however beyond expected in a Norwegian general population sample [51], and similar to the last updated reference data on EORTC in Norway [30]. The new breast module QLQ-BR45 was not available in Norwegian, and our translation of specific items could be suboptimal.

Strengths of this study are the large sample size and the high representativity to the general population. We performed age- and gender stratified random sampling from the Norwegian population and included a large sample ensuring high statistical power in subgroup analyses. Following advice from previous studies [5, 27], morbidity was registered in more detail by adding information on its influence on daily functioning [39]. Our final national sample of 5,135 participants is the largest normative EORTC study in Europe and is the first to include sexual health as an important aspect of HROoL.

Conclusion

The present study presents updated Norwegian normative general population data for the EORTC QLQ-C30 and is the first to provide normative values for the EORTC sexual health questionnaire QLQ-SHQ22 and the sexual subscales of the breast modules QLQ-BR23 and QLQ-BR45, for all separately in age groups by gender and morbidity. Normative values can serve as a support when interpreting HRQoL profiles in Norwegian cancer populations.

Availability of data and materials

The data are available on request to the corresponding author, randi.j.reidunsdatter@ntnu.no.

Legends to Figures

Figure IA

EORTC QLQ-C30 - Mean scores of all the functional scales and the most prominent symptoms for men and women in the Norwegian general population, presented in 10-years age groups from 29-79 years. Error bars represent mean scores with 95% confidence intervals. Higher scores on functional scales indicate better functioning and higher scores on symptom scales implies more symptom burden.

Figure IB

EORTC QLQ-C30 - Mean scores of all the functional scales and the most prominent symptoms for persons with and without morbidities in the Norwegian general population, presented in 10-years age groups from 29-79 years. Morbidity is based on the criteria of having one or more conditions that causes limitations in activity. Error bars represent mean scores with 95% confidence intervals. Higher scores on functional scales indicate better functioning and higher scores on symptom scales implies more symptom burden.

Figure IIA

EORTC QLQ-SHQ22, QLQ-BR23 and QLQ-BR45 - Mean scores of functional and symptom scales for men and women in the Norwegian general population, presented in 10years age groups from 29-79 years. Error bars represent mean scores with 95% confidence intervals. Higher scores on functional scales indicate better functioning and higher scores on symptom scales implies more symptom burden. For QLQ-SHQ22 all scales are presented, for QLQ-BR23/45 only scales applicable for the general population are included.

Figure IIB

EORTC QLQ-SHQ22, QLQ-BR23 and QLQ-BR45 - Mean scores of functional and symptom scales for persons with and without morbidities in the Norwegian general population, presented in 10-years age groups from 29-79 years. Morbidity is based on the criteria of having one or more conditions that causes limitations in activity. Error bars represent mean scores with 95% confidence intervals. Higher scores on functional scales indicate better functioning and higher scores on symptom scales implies more symptom burden. For QLQ-SHQ22 all scales are presented, for QLQ-BR23/45 only scales applicable for the general population are included.

References

- [1] Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes: John Wiley & Sons; 2013.
- [2] Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2:137-44. https://doi.org/10.4103/2229-3485.86879
- [3] Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178-86. https://doi.org/10.1200/JCO.2005.05.2951
- [4] Basch E. Missing patients' symptoms in cancer care delivery—the importance of patientreported outcomes. JAMA oncology. 2016;2:433-4.
- [5] Pilz MJ, Gamper EM, Efficace F, Arraras JI, Nolte S, Liegl G, et al. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. BMC Public Health. 2022;22:1040. https://doi.org/10.1186/s12889-022-13211-y
- [6] Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016;34:557-65. https://doi.org/10.1200/JCO.2015.63.0830
- [7] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute. 1993;85:365-76. https://doi.org/10.1093/jnci/85.5.365
- [8] Sprangers M, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific qualityof-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756-68. https://doi.org/10.1200/JCO.1996.14.10.2756
- [9] Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa R, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020;31:283-8.
- [10] Graupner C, Breukink S, Mul S, Claessens D, Slok A, Kimman M. Patient-reported outcome measures in oncology: a qualitative study of the healthcare professional's perspective. Support Care Cancer. 2021;29:5253-61. https://doi.org/10.1007/s00520-021-06052-9
- [11] Nguyen H, Butow P, Dhillon H, Sundaresan P. A review of the barriers to using Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs) in routine cancer care. Journal of Medical Radiation Sciences. 2021;68:186-95. https://doi.org/10.1002/jmrs.421
- [12] Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research. BMJ Qual Saf. 2014;23:508-18. https://doi.org/10.1136/bmjqs-2013-002524
- [13] Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-44. https://doi.org/10.1200/JCO.1998.16.1.139
- [14] Ahn S, Park B, Noh D, Nam S, Lee E, Lee M, et al. Health-related quality of life in disease-free survivors of breast cancer with the general population. Ann Oncol. 2007;18:173-82. https://doi.org/10.1093/annonc/mdl333

- [15] Alawadi SA, Ohaeri JU. Health related quality of life of Kuwaiti women with breast cancer: a comparative study using the EORTC Quality of Life Questionnaire. BMC Cancer. 2009;9:222. https://doi.org/10.1186/1471-2407-9-222
- [16] Giesinger JM, Loth FL, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1-8.


https://doi.org/10.1016/j.jclinepi.2019.10.003


- [17] Mols F, Husson O, Oudejans M, Vlooswijk C, Horevoorts N, van de Poll-Franse LV. Reference data of the EORTC QLQ-C30 questionnaire: five consecutive annual assessments of approximately 2000 representative Dutch men and women. Acta Oncol. 2018;57:1381-91. https://doi.org/10.1080/0284186X.2018.1481293
- [18] Velenik V, Secerov-Ermenc A, But-Hadzic J, Zadnik V. Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general Slovenian population. Radiology and oncology. 2017;51:342-50. https://doi.org/10.1515/raon-2017-0021
- [19] Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Grønvold M. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res. 2014;23:2183-93. https://doi.org/10.1007/s11136-014-0675-y
- [20] Lehmann J, Giesinger JM, Nolte S, Sztankay M, Wintner LM, Liegl G, et al. Normative data for the EORTC QLQ-C30 from the Austrian general population. Health and Quality of Life Outcomes. 2020;18:1-9. https://doi.org/10.1186/s12955-020-01524-8
- [21] Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer. 2002;11:307-26. https://doi.org/10.1002/pon.572
- [22] Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health. 2009;12:763-72. https://doi.org/10.1111/j.1524-4733.2008.00483.x
- [23] Sousa Rodrigues Guedes T, Barbosa Otoni Gonçalves Guedes M, de Castro Santana R, Costa da Silva JF, Almeida Gomes Dantas A, Ochandorena-Acha M, et al. Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies. Int J Environ Res Public Health. 2022;19:11921. https://doi.org/10.3390/ijerph191911921
- [24] van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47:667-75. https://doi.org/10.1016/j.ejca.2010.11.004 [25] Greimel E, Nagele E, Lanceley A, Oberguggenberger AS, Nordin A, Kuljanic K, et al. Psychometric validation of the European Organisation for Research and Treatment of Cancer—Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). Eur J Cancer. 2021;154:235-45. https://doi.org/10.1016/j.ejca.2021.06.003
- [26] Pilz MJ, Gamper E-M, Efficace F, Arraras JI, Nolte S, Liegl G, et al. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. BMC Public Health. 2022;22:1-12.
- [27] Arraras JI, Nolte S, Liegl G, Rose M, Manterola A, Illarramendi JJ, et al. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition. Health Qual Life Outcomes. 2021;19:208. https://doi.org/10.1186/s12955-021-
- [28] Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol. 2012;51:10-6. https://doi.org/10.3109/0284186X.2011.614636


- [29] Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345-51.
- [30] Fosså SD, Lothe Hess S, Dahl AA, Hjermstad MJ, Veenstra M. Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta oncologica. 2007;46:452-61.
- [31] Nolte S, Liegl G, Petersen M, Aaronson N, Costantini A, Fayers P, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153-63. https://doi.org/10.1016/j.ejca.2018.11.024
- [32] Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ= C30 (+ 3). J Clin Oncol. 1998;16:1188-96. https://doi.org/10.1200/JCO.1998.16.3.1188
- [33] Ficko SL, Pejsa V, Zadnik V. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires. Radiology and Oncology. 2019;53:337.
- [34] Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30: reference values from a large sample of the Swedish population. Acta Oncol. 2000;39:477-84. https://doi.org/10.1080/028418600750013384
- [35] Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016;69:28-38.
- [36] Waldmann A, Schubert D, Katalinic A. Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. PLoS One. 2013;8:e74149. https://doi.org/10.1371/journal.pone.0074149
- [37] Klee M, Grønvold M, Machin D. Quality of life of Danish women: population-based norms for the EORTC QLQ-C30. Qual Life Res. 1997;6:0-.
- [38] Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta oncologica. 2014;53:958-65.
- [39] Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2003;49:156-63. https://doi.org/10.1002/art.10993
- [40] Oberguggenberger AS, Nagele E, Inwald EC, Tomaszewski K, Lanceley A, Nordin A, et al. Phase 1–3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22. Cancer medicine. 2018;7:635-45. https://doi.org/10.1002/cam4.1338
- [41] Fayers P, Aaronson NK, Bjordal K, Sullivan M. EORTC QLQ-C30 scoring manual: European Organisation for Research and Treatment of Cancer; 1995.
- [42] Arraras JI, Nolte S, Liegl G, Rose M, Manterola A, Illarramendi JJ, et al. Spanish General Population Normative Data Analysis for the EORTC QLQ-C30 and Relationships Between Sex, Age, and Health Conditions. 2021.
- [43] Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, et al. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general


population reference values. Med J Aust. 2019;210:499-506. https://doi.org/10.5694/mja2.50207


- [44] Ficko SL, Pejsa V, Zadnik V. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires. Radiology and oncology. 2019;53:337-47. https://doi.org/10.2478/raon-2019-0047
- [45] Dahl AA, Grotmol KS, Hjermstad MJ, Kiserud CE, Loge JH. Norwegian reference data on the Fatigue Questionnaire and the Patient Health Questionnaire-9 and their interrelationship. Annals of General Psychiatry. 2020;19:1-9.
- [46] Jacobsen EL, Bye A, Aass N, Fosså SD, Grotmol KS, Kaasa S, et al. Norwegian reference values for the Short-Form Health Survey 36: development over time. Quality of Life Research. 2018;27:1201-12.
- [47] Nolte S, Waldmann A, Liegl G, Petersen MA, Groenvold M, Rose M, et al. Updated EORTC QLQ-C30 general population norm data for Germany. Eur J Cancer. 2020;137:161-70. https://doi.org/10.1016/j.ejca.2020.06.002
- [48] Yun YH, Kim SH, Lee KM, Park SM, Kim YM. Age, sex, and comorbidities were considered in comparing reference data for health-related quality of life in the general and cancer populations. J Clin Epidemiol. 2007;60:1164-75.
- [49] Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, et al. Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. J Womens Health. 2019;28:432-43.
- [50] Krouwel E, Albers L, Nicolai M, Putter H, Osanto S, Pelger R, et al. Discussing sexual health in the medical oncologist's practice: exploring current practice and challenges. J Cancer Educ. 2020;35:1072-88.
- [51] Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Torén K, Kongerud J, et al. Non-response in a cross-sectional study of respiratory health in Norway. BMJ open. 2016;6:e009912.














Table I Response by sex and age

		Approached	Answered	Response
		(n)	(n)	rate (%)
Total		15627	5135	32.86
Women		7900	2735	34.62
Men		7727	2400	31.06
Age				
group	18-29	2652	781	29.45
	30-39	2733	820	30.00
	40-49	2462	876	35.58
	50-59	2790	1016	36.42
	60-69	2733	981	35.89
	70-80	2257	661	29.29

Table II Sample characteristics for the Norwegian general population

		Total sample N (%)	Men n (%)	Women n (%)
Participants Age, mean, (SD)		5.135 (100%) 49.0 (16.5)	2.400 (46.7%)	2735 (53.3%)
Age categories	18–29 years	781 (15.2%)	300 (12.5%)	481 (17.6%)
	30–39 years	820 (16.0%)	337 (14.0%)	483 (17.7%)
	40–49 years	876 (17.0%)	370 (15.4%)	506 (18.5%)
	50–59 years	1016 (19.8%)	476 (19.8%)	540 (19.7%)
	60–69 years	981 (19.1%)	527 (22.0%)	454 (16.6%)
	70-70 years	661 (12.9%)	390 (16.3%)	271 (9.9%)
Education	Compulsory or less	294 (5.8%)	168 (7.0%)	126 (4.6%)
	Some post compulsories	1007 (19.7%)	534 (22.4%)	473 (17.4%)
	Post compulsory below university	1071(21.0%)	512 (21.3%)	559 (20.4%)
	University degree	1283 (25.0%)	604 (25.2%)	679 (24.9%)
	Postgraduate degree	1450 (28.4%)	565 (23.5%)	885 (32.5%)
Employment status	Employed full-time	2824 (55.0%)	1426 (59.4%)	1398 (51.2%)
	Employed part-time	599 (11.6%)	207 (8.6%)	392 (14.3%)
	Homemaker	100 (2.0%)	33 (1.4%)	67 (2.5%)
	Student	413 (8.1%)	138 (5.8%)	275 (10.1%)
	Unemployed	86 (1.7%)	41 (1.7%)	45 (1.7%)
	Retired	985 (19.2%)	557 (23.2%)	428 (15.7%)
	Full time sick leave	122 (2.4%)	41 (1.7%)	81 (3.0%)
	Part time sick leave	74 (1.4%)	20 (0.8%)	54 (2.0%)
	Disability pension	369 (7.2%)	111 (4.6%)	258 (9.5%)
	Occupational rehabilitation	46 (0.9%)	23 (1.0%)	23 (0.8%)
Relationship status	Single/not in a steady relationship	864 (16.9%)	396 (16.6%)	468 (17.1%)
	Married or in a steady relationship	3747 (73.4)	1798 (75.3%)	1949 (71.6%)
	Separated/divorced	340 (6.7%)	142 (5.9%)	198 (7.2%)
	Widowed	157 (3.1%)	51 (2.1%)	106 (3.9%)
Health status	Morbidities 1*	1378 (26.8%)	574 (24.9%)	804 (29.4%)
	Morbidities 2**	3120 (60.9%)	1314 (54.9%)	1806 (66.1%)
	Cancer	453 (8.8%)	228 (9.5%)	225 (8.2%)
	Heart disease	334 (6.5%)	244 (10.2%)	90 (3.2%)
	High blood pressure	1356 (26.4%)	742 (30.9%)	614 (22.4%)
	Pulmonary disease	623 (12.1%)	284 (11.8%)	339 (12.4%)
	Migraine	1317 (25.6%)	417 (17.4%)	900 (32.9%)

Diabetes	311 (6.1%)	167 (7.0%)	144 (5.3%)
Kidney disease	180 (3.5%)	97 (4.0%)	83 (3.0%)
Gastric ulcer or intestinal disease	460 (8.9%)	214 (8.9%)	246 (9.0%)
Arthrosis	905 (17.6%)	363 (15.1%)	542 (19.8%)
Epilepsy	68 (1.3%)	28 (1.2%)	40 (1.4%)
Stroke or cerebral hemorrhage	116 (2.2%)	72 (3.0%)	44 (1.6%)
Depression	1358 (26.5%)	445 (18.5%)	913 (33.4%)
Other psychological issues	982 (19.1%)	303 (12.6%)	679 (24.8%)
Rheumatic disease	394 (7.6%)	148 (6.1%)	246 (9.0%)

^{*}Morbidities 1 are based on the criteria of having one or more of the given conditions that limits activities.

^{**}Morbidities 2 are based on the criteria of having one or more of the given conditions. The presence of each condition has the same criteria as Morbidities 2.

Table III Reference values for EORTC QLQ-C30 by sex and age groups

					Femal	e						Male				
		Total	All	18-29	30-39	40-49	50-59	60-69	70-79	All	18-29	30-39	40-49	50-59	60-69	70-79
			wome	years	years	years	years	years	years	men	years	years	years	years	years	years
Functional scales QLQ-0	720		n													
Physical functioning	.30 M	90.6	89.4	91.7	91.7	90.2	88.5	89.0	82.5	91.9	94.7	95.0	95.0	92.1	90.4	85.7
i nysicai functioning	SD	14.8	15.0	13.6	13.0	15.6	15.3	13.7	18.5	14.5	9.1	10.1	11.8	15.8	15.9	18.1
Role Functioning	M	86.8	85.0	83.6	85.4	83.8	83.6	88.6	85.7	88.9	88.9	88.4	89.3	88.7	89.3	88.7
Ttore I unit troining	SD	23.3	24.3	24.7	23.4	25.8	25.6	21.2	23.7	21.9	19.3	22.1	23.2	24.5	20.6	20.6
Emotional functioning	M	80.9	78.2	69.5	75.1	78.0	81.1	83.8	84.6	84.0	78.9	79.8	82.1	84.1	87.5	88.6
Č	SD	20.2	20.9	24.4	21.5	19.6	19.3	17.8	17.2	19.0	22.9	20.7	19.7	18.8	16.8	13.8
Cognitive functioning	M	83.8	81.6	75.0	79.5	80.8	83.6	86.8	86.0	86.2	82.9	85.5	87.2	86.7	88.1	85.
8	SD	20.5	22.1	26.8	22.7	23.1	19.6	17.6	16.9	18.2	22.2	20.1	18.1	18.3	16.0	15.2
Social functioning	M	85.1	83.3	84.5	83.3	80.5	81.6	85.8	85.3	87.3	89.7	89.0	87.8	86.8	86.6	85.0
· ·	SD	23.2	24.2	23.8	24.0	26.1	25.0	21.7	22.7	21.9	18.7	21.3	22.2	23.0	22.5	22.0
Global health / QOL	M	73.0	71.1	67.1	68.8	70.7	71.2	75.3	76.0	75.2	71.1	72.8	74.3	76.3	77.5	76.8
	SD	21.9	22.3	22.4	21.8	22.0	23.6	21.1	21.4	21.3	20.0	21.1	22.1	21.6	21.8	19.9
Symptom scales QLQ-C	30															
Fatigue	M	30.4	33.9	42.5	36.4	33.8	32.8	27.0	27.8	26.4	31.1	29.6	26.7	25.5	23.8	24.5
	SD	23.8	24.8	26.4	24.1	24.8	25.2	21.4	21.9	21.9	22.7	22.9	22.8	22.1	21.1	19.8
Nausea / vomiting	M	4.81	5.88	10.15	7.34	5.29	5.06	2.92	3.5	3.6	6.5	4.3	3.0	3.0	2.9	3.1
	SD	11.6	12.7	16.2	15.4	11.5	10.7	8.1	10.3	9.9	13.0	11.0	9.2	9.3	8.8	8.8
Pain	M	21.9	24.1	18.3	21.1	25.1	28.1	25.8	27.2	19.4	15.4	16.6	17.1	19.9	22.6	21.8
	SD	25.7	26.6	23.8	25.2	28.1	28.5	25.7	26.5	24.3	19.4	22.6	24.7	26.3	25.4	24.0
Dyspnea	M	13.0	12.1	12.9	11.0	10.3	11.4	11.8	18.1	14.1	11.8	11.4	10.9	13.8	14.5	21.0
	SD	22.0	21.1	22.2	20.6	18.9	21.3	19.9	24.2	22.9	20.5	20.8	19.5	22.5	24.0	26.6
Insomnia	M	26.8	30.2	31.4	27.0	27.1	33.3	31.9	30.4	23.0	27.3	24.3	22.7	23.8	20.4	21.4
	SD	29.3	29.8	32.3	29.1	29.2	28.9	30.1	27.9	28.3	30.8	29.3	28.6	29.6	25.8	26.6
Appetite loss	M	9.6	11.7	22.0	13.0	10.6	9.20	6.2	7.31	7.3	16.1	9.0	7.6	5.6	4.8	4.2
	SD	20.3	22.2	29.9	22.7	21.1	18.6	15.5	16.0	17.7	24.5	19.5	19.0	15.2	14.0	12.7
Constipation	M	12.9	16.1	15.8	15.6	15.1	15.7	15.8	20.8	9.2	9.7	7.3	7.3	8.1	9.5	13.3
	SD	22.9	25.5	25.7	24.8	24.4	26.1	25.7	26.6	18.8	20.4	16.3	17.3	16.5	19.5	21.9
Diarrhea	M	14.7	14.8	16.5	13.6	13.6	14.7	15.3	15.8	14.6	11.8	14.8	13.7	15.5	14.7	16.5
	SD	22.2	22.7	23.3	21.3	20.6	24.0	23.0	24.1	21.6	19.6	22.4	21.7	21.8	21.9	21.7
Financial problems	M	8.2	9.2	8.7	8.3	11.8	12.0	8.2	3.1	7.0	6.9	8.6	7.4	8.7	6.2	4.2
	SD	21.4	22.7	21.7	20.7	26.2	26.2	20.5	13.6	19.7	18.6	22.8	20.4	22.1	18.4	14.2

Table IV: Regression model for the EORTC QLQ-C30 values by age, sex and morbidity

	Intercept	ept Age		Age	squared	S	Sex	Age-	-by-sex	Mor	bidity
		Coeff.	p-value.	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value
Physical functioning	95.70	0.03	0.44	-0.00	0.00	2.05	0.01	0.00	0.79	-14.89	0.00
Role functioning	90.78	-0.11	0.12	0.00	0.00	3.15	0.02	-0.03	0.43	-22.32	0.00
Emotional functioning	74.06	0.30	0.00	0.00	0.58	5.26	0.00	-0.06	0.06	-18.14	0.00
Cognitive functioning	77.68	0.38	0.00	-0.00	0.06	7.34	0.00	-0.14	0.00	-16.74	0.00
Social functioning	92.95	-0.34	0.00	0.01	0.00	4.98	0.00	-0.08	0.02	-25.52	0.00
Global QOL	73.21	0.05	0.42	0.00	0.00	2.55	0.03	-0.02	0.52	-23.09	0.00
Fatigue	37.39	-0.36	0.00	0.00	0.77	-8.44	0.00	0.11	0.00	22.47	0.00
Nausea/vomiting	10.19	-0.28	0.00	0.00	0.00	-3.60	0.00	0.07	0.00	5.67	0.00
Pain	8.56	0.53	0.00	-0.01	0.00	-1.77	0.21	-0.07	0.10	24.86	0.00
Dyspnoea	9.48	-0.26	0.00	0.00	0.00	0.73	0.57	0.06	0.12	16.21	0.00
Insomnia	22.88	0.03	0.74	0.00	0.87	0.81	0.63	-0.20	0.00	22.71	0.00
Appetite loss	21.59	-0.70	0.00	0.00	0.00	-4.34	0.00	0.05	0.10	11.73	0.00
Diarrhoea	12.91	-0.05	0.47	0.00	0.57	-0.97	0.47	0.04	0.30	9.25	0.00
Constipation	15.23	-0.24	0.00	0.00	0.00	-6.52	0.00	-0.00	0.92	9.22	0.00
Financial problems	0.54	0.46	0.00	-0.00	0.00	-0.21	0.86	-0.02	0.64	18.24	0.00

The age variable in the regression model starts at years above 18. The following equation estimates the physical functioning in a woman aged 50, with one or more health condition affecting daily functioning: Physical functioning (predicted) = $95.70 + \sec^2 2.05 + (age-18) \cdot 0.03 + (age-18) \cdot 2 \cdot -0.00 + \sec^2 (age-18) \cdot -0.00 + health condition* -14.89.$ Physical functioning (predicted) = 95.70 + 0 (female)*2.05 + $(50-18) \cdot 0.03 + (50-18) \cdot 2 \cdot -0.00 + 0 \cdot (50-18) \cdot -0.00 + 1$ (one or more health condition) - 14.89.

Table IV Reference values for EORTC QLQ-SHQ22 and for the sexual scales in QLQ-BR23 and QLQ-BR45

		_		7	Women							Men				
		All	18-29	30-39	40-49	50-59	60-69	70-79	All	18-29	30-39	40-49	50-59	60-69	70-79	Total
		women	years	years	years	years	years	years	men	years	years	years	years	years	years	
Functional scales QLQ-SHQ22																
Sexual satisfaction	M	53.3	56.7	57.4	55.6	51.1	48.4	48.2	57.7	60.9	62.5	60.0	59.6	55.5	49.5	57.7
	SD	26.0	25.1	23.2	26.6	27.3	25.6	26.3	25.5	26.1	23.8	23.9	25.8	25.2	26.0	25.9
Importance of Sexual. Activity	M	48.5	54.3	61.2	46.6	46.6	38.4	25.3	60.6	56.5	68.0	69.1	65.2	57.3	48.3	54.2
•	SD	33.3	33.4	30.6	32.4	32.4	30.8	29.0	31.9	33.7	30.2	29.4	30.2	31.0	32.3	33.2
Libido	M	61.8	72.5	65.3	63.7	63.7	55.4	49.9	76.8	85.2	82.4	83.4	79.3	73.4	60.8	68.8
	SD	33.6	31.6	31.7	33.5	33.5	33.3	34.4	29.0	24.6	24.6	25.5	27.5	29.0	33.5	32.4
Treatment*	M	78.7	88.2	93.3	75.7	75.7	75.2	80.7	78.2	88.0	87.8	88.8	81.0	70.9	63.8	78.4
	SD	32.6	24.9	16.5	34.4	34.4	33.6	32.4	33.7	24.5	27.3	24.6	30.7	37.2	39.8	33.0
Communication with professionals	M	6.7	13.0	6.7	4.8	5.4	5.1	3.6	6.0	7.9	4.3	3.7	5.3	7.0	7.9	6.3
-	SD	16.5	22.3	16.5	12.9	15.8	13.4	12.6	15.8	17.3	12.0	11.8	14.6	15.8	18.0	15.9
Security with partner	M	79.9	72.9	77.4	83.8	83.8	81.5	79.1	75.2	74.9	76.9	79.5	77.4	73.7	68.8	77.7
•	SD	26.6	28.6	28.3	24.1	24.1	26.6	26.7	28.7	28.9	30.4	25.2	28.0	29.8	29.0	27.7
Confidence erection	M	_	_	-	-	-	-	-	66.9	72.4	78.5	75.0	67.0	60.0	50.9	-
	SD	_	_	-	-	-	-	-	34.1	33.7	31.0	31.1	33.2	34.3	34.1	-
Femininity/ Masculinity	M	80.9	85.8	82.6	77.2	77.2	82.3	79.9	79.5	88.6	82.9	87.6	80.5	76.6	66.4	-
	SD	30.7	28.1	29.4	34.4	34.4	28.6	34.2	30.6	25.2	29.5	24.3	30.3	32.1	33.1	-
Symptom scales QLQ-SHQ22																
Sexual pain	M	10.3	15.4	8.2	7.3	7.3	12.2	9.8	2.5	3.8	2.4	2.0	2.1	2.4	2.6	6.6
•	SD	19.0	21.8	15.3	16.0	16.0	21.3	20.6	8.5	11.1	7.2	7.9	6.9	8.1	9.9	15.5
Worry Incontinence	M	14.9	7.6	12.4	15.9	15.9	16.0	24.4	9.1	2.5	5.0	5.0	9.4	12.5	16.4	12.2
•	SD	24.9	18.8	22.8	26.0	25.9	25.2	29.5	19.3	9.6	14.4	13.1	19.6	22.4	24.6	22.7
Fatigue	M	32.4	29.8	39.7	35.7	35.7	26.1	22.5	20.1	15.8	22.7	19.8	20.7	19.9	21.1	26.7
	SD	32.8	33.6	33.1	32.4	32.4	30.4	29.3	26.9	24.7	28.2	26.6	26.4	26.7	28.1	30.8
Vaginal Dryness	M	22.5	19.5	17.2	16.7	16.7	32.1	32.9	-	-	-	-	-	-	-	-
	SD	27.0	24.0	24.3	24.4	24.4	29.1	28.6	-	-	-	-	-	-	-	-
Functional scales QLQ-BR23																
Body Image	M	70.6	62.1	64.8	69.8	72.8	77.7	82.0	85.1	80.4	82.2	85.0	84.7	87.6	88.8	77.4
-	SD	27.3	29.9	28.7	26.4	26.3	24.3	21.9	18.9	21.4	20.7	17.5	19.6	17.3	16.2	24.8
Sexual Functioning	M	47.5	54.5	52.4	49.7	44.4	41.8	38.0	58.3	58.3	63.4	62.8	60.2	55.6	51.1	52.6
Č	SD	25.6	24.7	24.0	24.4	26.2	24.8	26.6	24.3	25.5	23.9	22.7	23.0	23.6	25.7	25.6
Sexual Enjoyment	M	70.7	70.4	71.1	73.8	71.0	67.7	67.3	75.9	75.4	77.5	79.1	77.1	74.2	72.1	73.2

	26.9	27.4	26.9	26.3	27.1	26.4	27.3	25.4	26.8	25.8	23.8	25.1	25.4	25.7	26.3
Symptom scales QLQ-BR45															
Endocrine Therapy Symptoms M	21.6	14.9	18.1	21.1	25.7	24.8	27.2	-	-	-	-	-	-	-	-
SD	18.6	14.9	17.5	19.1	19.8	18.2	18.9	-	-	-	-	-	-	-	-
Endocrine Sexual Symptoms M	18.1	19.5	14.4	13.0	19.0	23.9	23.0	-	-	-	-	-	-	-	-
SD	21.0	21.4	17.9	18.0	22.5	23.5	21.7	-	-	-	-	-	-	-	-

Supplementary Table I: Platform for participation in the survey

Participation by		Total sample N=5135	Men n=2400	Women n=2735
	National online health services	4961 (96.6%)	2305 (96.0%)	2656 (97.1%)
	DigiPost (digital postbox)	61 (1.2%)	35 (1.5%)	26 (1.0%)
	E-mail / Text message	71 (1.4%)	40 (1.7%)	31 (1.1%)
	Paper schemes by postal mail	42 (0.8%)	20 (0.8%)	22 (0.8%)

Supplementary Table II Floor and ceiling effect in the EORTC QLQ-C30 scales

	Lowest possible scores	Highest possible scores
	0 points (%)	100 points (%)
Physical functioning	0.0	50.0
Role functioning	1.7	67.3
Emotional functioning	0.4	30.8
Cognitive functioning	0.9	45.8
Social functioning	1.4	61.2
Global QLQ	0.5	18.2
Fatigue	17.8	1.8
Nausea/Vomiting	80.5	0.1
Pain	42.4	2.6
Dyspnea	69.2	1.5
Insomnia	44.6	5.8
Appetite loss	78.2	1.2
Constipation	71.0	2.0
Diarrhea	64.2	1.4
Financial problems	84.3	2.5

Supplementary Table III Floor and ceiling effect in the EORTC QLQ-SHQ22

	Lowest possible scores	Highest possible scores
	0 points	100 points
	(%)	(%)
Sexual satisfaction	2.5	2.6
Importance of sexual activity	16.0	21.8
Libido	9.7	41.0
Treatment	8.5	64.2
Communication with professionals	84.1	0.5
Security with partner	4.4	52.2
Confidence erection	11.3	41.3
Femininity/Masculinity	6.4	66.5
Masculinity	6.0	62.6
Sexual pain	76.9	0.4
Worry Incontinence	73.0	2.0
Fatigue	47.7	7.1
Vaginal dryness	51.0	3.3